Biotech product-liability insurance

Biotech product-liability insurance is the specialty coverage that protects biotechnology, pharmaceutical, medtech, CDMO and CRO companies against third-party bodily-injury and property-damage claims arising from their products, and it is underwritten against the specific risk profile of an FDA, EMA or NMPA-regulated portfolio. Because a single adverse-event cluster can exceed the balance sheet of a clinical-stage biotech, the market structures coverage as layered towers, with Aon publishing five distinct pharmaceutical-liability tower structures for 2026 sized by company type. Carriers such as Chubb have responded with dedicated packages, launching a Premier Life Science Package, while Sompo filed a Life Science Plus programme and Markel introduced a Life Science Combined product, signalling that life-sciences liability is now a separately traded class rather than a generic commercial line. A typical placement combines product liability, clinical-trial liability, errors-and-omissions and product recall, and increasingly evaluates captive insurance as an alternative to traditional third-party towers for mature biotech portfolios.

The key directions of biotech product-liability insurance are:

1. Product-liability coverage (Bodily injury cover): indemnity for claims of injury or damage caused by a marketed biologic, drug, device or diagnostic.
2. Clinical-trial liability (CTL) coverage (Trial subject injury): protection for sponsors, CROs and investigators against claims from injured trial subjects.
3. Errors-and-omissions and professional indemnity (E&O/PI): cover for financial loss caused by professional mistakes in design, manufacturing or regulatory work.
4. Captive and alternative risk transfer (Self-insurance): structured vehicles through which a biotech retains a layer of its own risk, reducing reliance on the commercial tower market.

Sectoral value chain#

[Exposure & risk assessment] ──> [Program design (tower)] ──> [Underwriting & placement] ──> [Policy bind & premium]
                                            │
                                  (Actuarial modeling)
                                            │
                                            ▼
[Renewal / captive review] <─── [Claims handling & defence] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Actuarial loss modeling: statistical models that price biotech bodily-injury severity and frequency from historical life-sciences loss data.
• Layered tower placement: broking technique that stacks primary and excess limits across multiple carriers to reach high total limits.
• Captive insurance structures: licensed subsidiary vehicles that let a biotech retain risk and access reinsurance markets directly.

The biotech liability stack is built on actuarial models, layered placement and alternative-risk structures that match cover to a high-severity, low-frequency loss profile.

1. Actuarial risk modeling:
   • Models price bodily-injury severity and frequency from historical life-sciences loss data, adjusted for product class (small molecule, biologic, cell-and-gene therapy, device) and regulatory pathway.
   • Digital-health and AI-enabled diagnostics are forcing carriers to add new loss-trend analytics, as Chubb’s digital-health risk research shows.
2. Layered tower placement:
   • Brokers stack a primary carrier (low attachment) under multiple excess layers to build total limits that a single carrier would not hold, sized by company stage.
   • Aon’s five 2026 tower structures codify how limits scale from pre-clinical biotech to commercial pharma.
3. Captive insurance structures:
   • A licensed captive subsidiary lets a biotech retain a layer of its own risk, smooth premium over time and access reinsurance markets directly.
   • Brokers run captive-versus-traditional analyses to decide whether self-insurance beats the commercial tower for a given portfolio.